BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 31692283)

  • 1. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
    J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
    J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
    Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
    World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 11. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D; Zhang Y; Li H; Cheng L
    Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
    Li XS; Nie KC; Zheng ZH; Zhou RS; Huang YS; Ye ZJ; He F; Tang Y
    BMC Cancer; 2021 Jan; 21(1):96. PubMed ID: 33485313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study.
    Talvitie EM; Vilhonen H; Kurki S; Karlsson A; Orte K; Almangush A; Mohamed H; Liljeroos L; Singh Y; Leivo I; Laitinen T; Kallajoki M; Taimen P
    Neoplasia; 2020 Sep; 22(9):333-342. PubMed ID: 32585428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.